Calnifit Tablet (Calcium Lysinate + Vitamin D3).

• Composition :
  Each Tablet contains: Calcium lysinate equivalent to elemental calcium 250mg + Vitamin D3 400 IU.
• Indications :
  For the treatment of calcium and Vitamin D deficiency states
• Pharmacodynamics :
  Calcium is essential for maintaining the functional integrity of nervous, muscular, and skeletal system. Vitamin D exerts it`s action by influencing calcium homoeostasis.
• Dosage and administration :
  One tablet daily with food
• Contraindications :
  This product is contraindicated in patients with known hypersensitivity to any of the ingredients. Hypercalcaemia, Hypercalciuria or hypophosphatemia, Nephrocalcinosis or Nephrolithiasis, Malabsorption syndrome.
• Precautions and warnings :
  Vitamin D3 should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. Calcium/vitamin D3 should be used with caution in patients suffering from sarcoidosis because of the risk of increased metabolism of vitamin D to its active metabolite.
• Use in pregnancy, lactation & pediatrics :
  Vitamin D is likely safe during pregnancy when used in daily amounts below 4,000 units. The recommended dose of calcium during pregnancy is 1,000 mg and the upper safe limit is 2,500 mg. Calcium and vitamin D3 pass into human milk. Vitamin D is probably safe during breastfeeding when used in daily amounts below 4,000 units. The upper safe limit of calcium during lactation is 2,500 mg. The safe upper limit for vitamin D is 1,000 to 1,500 IU/day for infants, 2,500 to 3,000 IU/day for children aged 1 to 8 years, and 4,000 IU/day for children 9 years and older. The safe upper limit of calcium is 1,000 to 1,500 mg in infants; 2,500 mg in children aged 1 to 8 years and 3,000 in children aged 9 to 18 years.
• Drug interactions :
  cholestyramine or laxatives such as paraffin oil may reduce the gastrointestinal absorption of vitamin D. Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
• Adverse reactions :
  Generally, this preparation is well tolerated. Constipation or stomach upset may occur. Other side effects that may occur are nausea/vomiting, loss of appetite, dyspepsia, flatulence.
• Therapy Area :
  Nutraceuticals and Immunoceuticals